Researchers with funding from Fight for Sight have demonstrated that a new drug treatment for cystic fibrosis and Duchenne muscular dystrophy can override a genetic fault that causes choroideremia – a ...

DUBLIN--(BUSINESS WIRE)--The "Choroideremia - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering. This report outlays comprehensive insights of present clinical ...

Ocular gene transfer clinical trials are raising patient hopes for the treatment of choroideremia – a blinding degenerative retinopathy. Phase I choroideremia gene transfer trials necessitate ...

EMERYVILLE, Calif.--(BUSINESS WIRE)--4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV gene medicines based on directed evolution, announced that the ...

An experimental gene therapy continued to improve the vision of some patients with choroideremia at 3.5 years of follow-up in a phase 1/2 clinical trial. In showing efficacy for this length of time, ...

CRF acquired Spark Therapeutics, Inc.’s SPK-7001 CHM gene therapy assets and is analyzing long-term data to identify key clinical measures for development ...

Choroideremia is a rare genetic condition that causes the eye to lose all layers of the retina, the thin layer of tissue on the back of the eye. Because the retina helps the eye focus light and turn ...

CRF awards four global grants to advance CHM research toward new clinical trial endpoints and therapeutic approaches—driving progress toward treatments. SPRINGFIELD ...

Canada's first human gene therapy trial for eyes -- the replacement of a faulty gene with a healthy one -- is now underway at the Royal Alexandra Hospital to preserve and potentially restore vision ...

Please provide your email address to receive an email when new articles are posted on . Koira Pharmaceuticals, in a new partnership with the Choroideremia Research Foundation, plans to accelerate its ...